Abstracts tagged "Biologic drugs"

Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
Sebastian C Rodriguez-Garcia¹, Raul Castellanos-Moreira Sr.¹, José Inciarte-Mundo², M. Victoria Hernández³, Virginia Ruiz-Esquide², Andrea Cuervo¹, Julio Ramírez², Juan Cañete¹, Jose Gomez Puerta¹ and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…
Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Jeffrey R. Curtis¹, Gregory St. John², Michael Pannucci², Yong Lin³, José A. Maldonado-Cocco⁴, Tom W.J. Huizinga⁵, Marina Stanislav⁶ and Paul Emery⁷, ¹University of Alabama, Birmingham, AL, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Universidad de Buenos Aires, Buenos Aires, Argentina, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Sarah L. Patterson¹, Michael Evans², Ishita Aggarwal³, Zara Izadi⁴, Milena Gianfrancesco⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California - San Francisco, San Francisco, CA, ³Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶San Francisco VA Medical Center, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
Abstract Number: 626 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis
Maria A. Lopez-Olivo¹, Aliza Matusevich², Scott B. Cantor³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ³Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Data on patient-reported functional ability to evaluate the optimal strategy for patients who have failed to first TNFi is scarce. Patient-reported outcomes are a…
Abstract Number: 2044 • 2018 ACR/ARHP Annual Meeting
Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies
Ivan Arias de la Rosa¹, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez², Maria Carmen Abalos-Aguilera¹, Yolanda Jiménez-Gómez², Irene Cecchi³, Rafaela Ortega-Castro², Miguel Angel Caracuel-Ruiz⁴, Jerusalem Calvo-Gutierrez², Alejandro Escudero-Contreras¹, Eduardo Collantes-Estévez², Chary Lopez-Pedrera⁴ and Nuria Barbarroja², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: Neutrophils are the most abundant cells in synovial fluid, having all the features of activated cells in rheumatoid arthritis (RA), including prolonged cell survival,…
Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Gregory St. John², Carol J. Etzel¹, Stefano Fiore³, Taylor Blachley¹, Toshio Kimura², Rajeshwari Punekar³, Kelechi Emeanuru⁴, Susan Boklage² and Joel Kremer^1,5, ¹Corrona LLC, Waltham, MA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi, Bridgewater, NJ, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…
Abstract Number: 627 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis
Burcu Yagız¹, Belkıs Nihan Coşkun², Sedat Kiraz³, Ihsan Ertenli⁴, Orhan Kucuksahin⁵, Ediz Dalkiliç⁶, Cemal Bes⁷, Nilufer Alpay Kanitez⁸, Timucin Kasifoglu⁹, Hakan Emmungil¹⁰, Pamir Atagunduz¹¹, Suleyman Serdar Koca¹², Muhammet Cinar¹³, Aşkın Ateş¹⁴, Servet Akar¹⁵, Onay Gercik¹⁶, Duygu Ersozlu Bakirli¹⁷, Veli Yazisiz¹⁸, Gezmis Kimyon¹⁹, Nazife Sule Yasar Bilge²⁰, Muge Aydin Tufan²¹, Ridvan Mercan²², Burak Oz¹², Zeynel Abidin Akar¹², Omer Karadag²³, Bahar Kelesoglu²⁴, Sedat Yılmaz²⁵, Sezin Turan²⁶, Yavuz Pehlivan², Ender Terzioglu²⁷, Levent Kilic²³, Sukran Erten²⁸, Koray Tascilar²⁹ and Umut Kalyoncu³⁰, ¹Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ²Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁴Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ⁵Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ⁶Department of Internal Medicine, Division of Rheumatology, Uludağ University Faculty of Medicine, Bursa, Turkey, ⁷Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁸Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ⁹Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ¹⁰Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ¹¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ¹²Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ¹³Division of Rheumatology, Gülhane Military Medical Academy, School of Medicine, Ankara, Turkey, ¹⁴Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ¹⁵Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹⁶Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ¹⁷PsART study group, Adana, Turkey, ¹⁸Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁹Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, ²⁰Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ²¹Rheumatology, Cukurova University School of Medicine, Adana, Turkey, ²²Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²⁴Rheumatology, Ankara University, Ankara, Turkey, ²⁵Division of Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, ²⁶Trakya University Medical Faculty, Edirne, Turkey, ²⁷Division of Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ²⁸PsART study group, Ankara, Turkey, ²⁹Rheumatology, Okmeydani Research and Training Hospital, Istanbul, Turkey, ³⁰Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory, systemic autoimmune disease that causes several health problems, such as pain, joint destruction and loss of function.…
Abstract Number: 2078 • 2018 ACR/ARHP Annual Meeting
Induction of Netosis in Ankylosing Spondylitis: Association to Disease Pathogenesis and Modulation By Anti-Tnfα Therapy
Patricia Ruiz-Limon¹, M. Carmen Castro-Villegas², Chary Lopez-Pedrera³, Rafaela Ortega-Castro⁴, Maria Carmen Abalos-Aguilera¹, Nuria Barbarroja⁴, Carlos Perez-Sanchez⁴, Ivan Arias de la Rosa¹, Alejandro Ibáñez-Costa³, Alejandra Maria Patiño-Trives³, Daniel Espejo-Peralbo¹, Pilar Font-Ugalde⁴, Jose Antonio Gonzalez-Reyes⁵, Jose Manuel Villalba⁵, Clementina López-Medina⁴, Alejandro Escudero-Contreras¹, Eduardo Collantes-Estévez⁴ and Yolanda Jiménez-Gómez⁴, ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Departamento de Biologia Celular, Fisiologia e Inmunología, University of Córdoba, Cordoba, Spain
Background/Purpose: NETosis has been suggested to play a central role in several rheumatology diseases. Nevertheless, this process, and its modulation in therapeutic response has not…
Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Daeria O. Lawson^1,2, Maria Eraso³, Lawrence Mbuagbaw⁴, Theresa Aves⁵, Alvin Leenus⁴, Marianinha Joanes⁶, Ahmed Omar^1,7 and Robert D Inman^8,9, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, Tornoto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ⁵St. Michael's Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Boston University School of Medicine, Boston, MA, United States, Boston, MA, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…
Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Magali Pacanowski Fournier¹, Antoine Brezin², Christophe Chiquet Sr.³, David Saadoun⁴, Jeremie Sellam⁵, Patrice Cacoub⁶, Pascal Sève⁷, Bahram Bodaghi Sr.⁸ and Laurent Kodjikian Sr.^9,10,11, ¹medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, ²Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, ³ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁷Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁸ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, ⁹ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, ¹⁰université Claude Bernard lyon 1, villeurbanne, France, ¹¹UMR-CNRS 5510 Matéis, villeurbanne, France
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Guro Løvik Goll¹, Nils Bolstad², Ines Iria^3,4, Rolf Klaasen⁵, Kristin Kaasen Jørgensen⁶, Inge C Olsen⁷, Ana Valido⁸, Maria J Saavedra⁹, João E. Fonseca¹⁰, Merete Lorentzen¹¹, Cato Mork¹², Knut EA Lundin¹³, David J Warren¹⁴, Espen A. Haavardsholm¹⁵, Jorgen Jahnsen¹⁶, Tore Kvien¹⁵ and João Gonçalves¹⁷, ¹Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ³Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, ⁴iMed- Research Institute for medicines, Lisbon, Portugal, ⁵Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ⁶Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹¹Dept of Dermatology, Rikshospitalet, Oslo, Norway, ¹²Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ¹³Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, ¹⁴Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ¹⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ¹⁷Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
Abstract Number: 2385 • 2018 ACR/ARHP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Mary Ellen Riordan⁵, Anne C. Dennos⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Brian M. Feldman⁹ and Yukiko Kimura⁵, ¹Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ²Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Duke University Medical Center, Durham, NC, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Parent Partner, Whitehouse Station, NJ, ⁸Parent Partner, San Francisco, CA, ⁹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: There is significant variation in the timing of when biologic medications are started during initial treatment for polyarticular juvenile idiopathic arthritis (P-JIA) in clinical…
Abstract Number: 703 • 2018 ACR/ARHP Annual Meeting
Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Anastasia Dupré¹, Michael Collins², Franck Carbonnel³, Xavier Mariette^4,5 and Raphaele Seror¹, ¹Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France, ²Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-Enterology, Université Paris Sud, Le Kremlin Bicêtre, France, ³Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-enterology, Université Paris Sud, Le Kremlin Bicêtre, France, ⁴Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France, ⁵Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France
Background/Purpose: Vedolizumab is a humanised IgG1 monoclonal antibody anti-α4β7 integrin agent used in inflammatory bowel disease (IBD). It modulates gut inflammation by preventing leukocyte migration…
Abstract Number: 2509 • 2018 ACR/ARHP Annual Meeting
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment
Mark C. Genovese¹, Hubert van Hoogstraten², Gregory St. John³, Qunming Dong², Juan José Gómez-Reino⁴, José A. Maldonado-Cocco⁵, Juan Carlos Salazar⁶, Tom W.J. Huizinga⁷ and Gerd R. Burmester⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Sanofi Genzyme, Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain, ⁵School of Medicine, Buenos Aires University, Buenos Aires, Argentina, ⁶Riesgo de Fractura S.A - CAYRE, Bogotá, Colombia, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Charité – University Medicine Berlin, Berlin, Germany
Background/Purpose: EXTEND (NCT01146652) is an ongoing open-label extension study enrolling patients completing five sarilumab originator studies (MOBILITY [NCT01061736]; TARGET [NCT01709578]; ASCERTAIN [NCT01768572]; ACT11575 [NCT01217814]; ONE…
Abstract Number: 960 • 2018 ACR/ARHP Annual Meeting
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
Andrei Barbulescu¹, Thomas Frisell¹, Johan Askling² and Bénédicte Delcoigne¹, ¹Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Gastrointestinal (GI) perforations occur more often than expected in patients with RA. Reports indicate that tocilizumab may be associated with an increased risk of…

1
2
3
…
12
Next Page »